AbbVie is a large, heavily covered U.S. pharmaceutical company, and its stock price target debate centers on whether its immunology pipeline can replace declining Humira revenue. Across roughly 30 analysts, individual targets range from about $247 to $325, with a calculated average near $293. That mean is barely above the current share price, which means the broad analyst consensus — a "Buy" rating on balance — already prices in most near-term upside.
Because the average analyst price target is so close to the market price, it does not represent a meaningful level for the stock to reach. Accordingly, the $320 figure used in this article is not an analyst consensus. It reflects the upper end of genuinely public bull-case discussion — firms including Scotiabank ($320, early October 2026), Barclays ($325), HSBC ($315), and Morgan Stanley ($310) — as well as a valuation argument that continued execution could warrant a modest re-rating toward the top of AbbVie's large-cap peer band. Bullish analysts point to Skyrizi and Rinvoq momentum, while cautious voices such as Goldman Sachs and RBC Capital flag weaker-than-expected efficacy data in some late-stage programs and crowded positioning.
AbbVie shares closed near $285.64, just below a 52-week range of $190.75 to $291.40 and carrying a market capitalization of roughly $505 billion and a forward dividend yield of about 2.4%. Reaching $320 implies upside of roughly 12% — a substantial move that would require the stock to break decisively through its recent record high and the psychologically important $300 level.
Fundamentally, the path depends on whether AbbVie can keep replacing lost Humira sales. In its second quarter, reported revenue rose about 10% to $16.99 billion while adjusted EPS (earnings per share) climbed roughly 23% to $3.65. Skyrizi and Rinvoq together generated about $8.03 billion, growing in the mid-20% range, while neuroscience assets including Vraylar, Qulipta, and the newer Vyalev posted strong growth. Sustaining that momentum — and translating it into multiple expansion rather than just earnings growth — is the core requirement for a move toward $320.
From a market-structure standpoint, AbbVie has rallied strongly off its 52-week low of $190.75 and now trades just under its 52-week high of $291.40. The $291–$300 zone is the critical resistance area; a sustained close above $300 would clear the prior record and open the path toward the $315–$325 region where the most bullish targets cluster. On the downside, the $275–$280 area is a near-term support zone, and a break below it would signal that momentum is fading before the target comes into view.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. The next major catalyst is AbbVie's third-quarter earnings report, scheduled for October 30, 2026. Investors should watch Skyrizi and Rinvoq sales growth, Humira's rate of decline, neuroscience traction, updated guidance, and any pipeline or regulatory updates. Analyst revisions around results will also matter, given how tightly the stock trades relative to its consensus target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a name like AbbVie that sits near record highs, such tools can help traders spot shifts in momentum and trend more efficiently than manual scanning. Traders use these signals to discover opportunities, monitor existing positions, and identify changing trends as they develop.
The question of whether AbbVie can reach $320 ultimately hinges on execution rather than the analyst consensus, which clusters near $293 and implies only modest upside. The $320 objective reflects the most optimistic, publicly discussed end of the range and would require roughly a 12% advance to new record highs. Strong immunology momentum and a broadening pipeline support the bull case, while Humira erosion, pricing pressure, and valuation near highs pose meaningful obstacles. The range of analyst targets — from about $247 to $325 — underscores real disagreement, and the upcoming earnings report and analyst revisions will be the key inputs to watch. No outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with JNJ. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then JNJ could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +1.41% | ||
| JNJ - ABBV | 51% Loosely correlated | -0.73% | ||
| NVS - ABBV | 49% Loosely correlated | -0.19% | ||
| AMGN - ABBV | 48% Loosely correlated | +1.15% | ||
| BMY - ABBV | 47% Loosely correlated | +1.78% | ||
| MRK - ABBV | 42% Loosely correlated | +2.18% | ||
More | ||||